Phaseline

Companies › AstraZeneca

AstraZeneca: clinical trials, targets and expected readouts

135 active drug programs in 1690 registered trials: 841 Phase 2, 385 Phase 3, 372 Phase 1, 92 Phase 4; Oncology, Other, Metabolic and endocrine, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Osimertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 4Non-small Cell Lung Cancer; Carcinoma; Metastatic Non-small Cell Lung Cancer; Cancer …Nov 2026
Benralizumab
Interleukin-5 receptor subunit alpha inhibitor
IL5RAPhase 4Asthma; Eosinophilic Asthma; Eosinophilic Granulomatous Vasculitis; Hypereosinophilic Syndrome …Nov 2026
Olaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 4Metastatic Castration-resistant Prostate Cancer; Advanced Ovarian Cancer; Platinum Sensitive; Endometrial Neoplasms …Nov 2026
Dapagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Chronic Kidney Disease; Heart Failure and Impaired Kidney Function; Chronic Kidney Disease and Hypertension; Type 2 Diabetes Mellitus …Dec 2026
Datopotamab Deruxtecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 4Stomatitis; Breast Cancer; Metastatic Non-small Cell Lung Cancer; Non-small Cell Lung Cancer …Dec 2026
Trastuzumab deruxtecan
Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor
ERBB2, TOP1Phase 4BREAST CANCER; Advanced or Metastatic Breast Cancer; Breast Neoplasms; Breast Cancer; HER2-positive; Metastatic …Dec 2026
Acalabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 4Chronic Lymphocytic Leukaemia; Untreated Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma; Mantle-cell Lymphoma …Jan 2027
Anifrolumab
Interferon-alpha/beta receptor alpha chain antagonist
IFNAR1Phase 4Systemic Lupus Erythematosus; Systemic Sclerosis; Lupus Nephritis; Cutaneous Lupus Erythematosus …Jan 2027
Albuterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 4AsthmaFeb 2027
Budesonide (PT027)
Glucocorticoid receptor agonist
NR3C1Phase 4Chronic Obstructive Pulmonary Disease; Asthma; Functional Dyspepsia; IgA Nephropathy …May 2027
Ravulizumab
Complement C5 inhibitor
C5Phase 4aHUS; Generalized Myasthenia Gravis; Delayed Graft Function; NMOSD …Jun 2027
Breztri Aerosphere
Triple combination: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonis
ADRB2, CHRM3Phase 4Moderate to Severe COPDDec 2027
Capivasertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 3Locally Advanced (Inoperable) or Metastatic Breast Cancer; Prostate Cancer; Triple Negative Breast Neoplasms; Breast Cancer …Nov 2026
AZD0901
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Gastric CancerNov 2026
Elecoglipron
Dipeptidyl peptidase-4 (DPP-4) inhibitor
DPP4, GCK, GCGRPhase 3Obesity; Type 2 Diabetes Mellitus; Weight Management; Heart Failure With Preserved Ejection Fraction (HFpEF) …Nov 2026
savolitinib
Hepatocyte growth factor receptor inhibitor
METPhase 3Carcinoma; Papillary Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Lung Cancer …Nov 2026
Durvalumab (MEDI4736)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 3Non Small Cell Lung Carcinoma NSCLC; Hepatocellular Carcinoma; Small Cell Lung Cancer; Biliary Tract Cancer …Nov 2026
Tremelimumab
Cytotoxic T-lymphocyte protein 4 inhibitor
CTLA4Phase 3Small Cell Lung Cancer; Hepatocellular Carcinoma; Advanced Hepatocellular Carcinoma; Non Small Cell Lung Carcinoma NSCLC …Nov 2026
eculizumab
Complement C5 inhibitor
C5Phase 3NMOSD; Neuromyelitis Optica Spectrum Disorder Attack; Neuromyelitis Optica Spectrum Disorders (NMOSD); Hypertensive Emergency-associated Hemolytic Uremic Syndrome …Dec 2026
baxdrostat
Aldosterone synthase inhibitor
CYP11B2Phase 3Primary Hyperaldosteronism; Uncontrolled Hypertension; Chronic Kidney Disease and HypertensionDec 2026
gefurulimab
CD23 antagonist monoclonal antibody
FCER2Phase 3Generalized Myasthenia GravisDec 2026
Bevacizumab
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Hepatocellular Carcinoma; Advanced Ovarian Cancer; Hepatocellular Carcinoma (HCC); Keloids …Dec 2026
ceralasertib
Serine-protein kinase ATR inhibitor
ATRPhase 3Advanced or Metastatic Non-Small Cell Lung Cancer; Metastatic Triple Negative Breast Cancer; Melanoma; Non-Small Cell Lung Cancer …Dec 2026
Fulvestrant
Estrogen receptor alpha antagonist; Estrogen receptor degrader
ESR1Phase 3Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Estrogen Receptor-positive Breast Cancer; Breast Cancer Metastatic …Dec 2026
Selumetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 3Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV; Neurofibromatosis 1; Advanced Non Small Cell Lung Cancer; Tumor …Dec 2026
AZD0780
PCSK9 inhibitor
PCSK9Phase 3Heterozygous Familial Hypercholesterolaemia; Cardiovascular Disease; DyslipidaemiaJan 2027
Eplontersen
Transthyretin mRNA antisense inhibitor
TTRPhase 3Transthyretin Amyloid Cardiomyopathy; Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Jan 2027
Monalizumab
NKG2-A/NKG2-B type II integral membrane protein inhibitor
KLRC1Phase 3Squamous Cell Carcinoma of the Head and Neck; Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Acute Myeloid Leukaemia …Jan 2027
Oleclumab
5'-nucleotidase inhibitor
NT5EPhase 3Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer (NSCLC); Triple Negative Breast Neoplasms …Jan 2027
Tezepelumab
Thymic stromal lymphopoietin inhibitor
TSLPPhase 3Chronic Rhinosinusitis With Nasal Polyps; Eosinophilic Esophagitis; Severe Asthma; Asthma …Jan 2027
Volrustomig (MEDI5752)
CTLA-4/PD-1 bispecific antibody
CTLA4, PDCD1, TIGITPhase 3Metastatic Non-small Cell Lung Cancer; Locally Advanced Cervical Cancer; Unresectable Pleural Mesothelioma; Locally Advanced Head and Neck Squamous Cell Carcinoma …Jan 2027
abiraterone acetate
Cytochrome P450 17A1 inhibitor
CYP17A1Phase 3Metastatic Castration-resistant Prostate CancerFeb 2027
Zibotentan
Endothelin receptor ET-A antagonist
EDNRAPhase 3Chronic Kidney Disease With High ProteinuriaFeb 2027
AZD2936 (rilvegostomig)
Anti-TIGIT/anti-PD-1 bispecific antibody
TIGIT, PDCD1Phase 3Non-small Cell Lung Cancer; Biliary Tract Cancer; Endometrial Cancer; HER2-positive Gastric Cancer …Mar 2027
CAEL-101
monoclonal antibody against misfolded light chain amyloid deposits
ALBPhase 3AL AmyloidosisApr 2027
Camizestrant (AZD9833)
Estrogen receptor alpha degrader
ESR1Phase 3Breast Cancer, Early Breast Cancer; ER-Positive HER2-Negative Breast Cancer; Advanced Breast Cancer; Advanced ER-Positive HER2-Negative Breast Cancer …Apr 2027
Danicopan
Complement factor D inhibitor
CFDPhase 3Paroxysmal Nocturnal HemoglobinuriaMay 2027
Rosuvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 3Hypercholesterolaemia; Acute Coronary Syndromes; Coronary Artery Disease; Statin Therapy …May 2027
Tozorakimab Dose Regimen 1
IL-13 receptor antagonist
IL13Phase 3Viral Lung Infection and Acute Respiratory Failure; Chronic Obstructive Pulmonary Disease; AsthmaJun 2027
eneboparatide
PTH1 receptor agonist (parathyroid hormone analog)
PTH1RPhase 3Chronic HypoparathyroidismJun 2027
Laroprovstat
Small molecule reducing LDL-C
–Phase 3HypercholesterolaemiaJul 2027
ALXN1720
Complement C5 inhibitor (recombinant monoclonal antibody)
–Phase 3Generalized Myasthenia GravisAug 2027
Puxitatug Samrotecan (AZD8205)
B7-H4-targeted antibody-drug conjugate (ADC)
B7H4Phase 3Endometrial Cancer; Breast CancerSep 2027
Saruparib
PARP inhibitor
PARP1, PARP2Phase 3Metastatic Castration-Sensitive Prostate Cancer; Advanced Breast Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Prostate Cancer …Sep 2027
AZD0120
BCMA/CD19 dual CAR T cell therapy
BCMA, CD19Phase 3Relapsed Refractory Multiple Myeloma; Newly Diagnosed Multiple Myeloma (NDMM); Newly Diagnosed Multiple Myeloma; Relapsed/Refractory Multiple Myeloma …Oct 2027
AZD5335
Anti-FRα antibody-drug conjugate
FOLR1Phase 3Epithelial Ovarian Cancer; Fallopian Tube CancerOct 2027
Sonesitatug vedotin–Phase 3Gastric Cancer; Gastroesophageal AdenocarcinomaNov 2027
BGF MDI 320/14.4/9.6 μg
Triple therapy: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonist (g
ADRB2, CHRM3Phase 3COPD (Chronic Obstructive Pulmonary Disease)Dec 2027
ALXN2220
anti-TTR monoclonal antibody
TTRPhase 3Transthyretin Amyloid CardiomyopathyDec 2027
surovatamig (AZD0486)
Bispecific monoclonal antibody targeting CD20 and CD3E
CD19, CD3E, CD20Phase 3Large B-cell Lymphoma; Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV; Untreated Follicular Lymphoma; B-cell Non-Hodgkin Lymphoma …Jan 2028
ALXN1850
Alkaline phosphatase enzyme replacement therapy
ALPLPhase 3HypophosphatasiaFeb 2028
Torvutatug samrotecan–Phase 3Platinum-sensitive Relapsed Epithelial Ovarian Cancer; Epithelial Ovarian Cancer; Ovarian CancerAug 2028
AZD6234 (Lenbelintide)
Glucagon receptor agonist
GCGRPhase 3Obesity or OverweightAug 2028
Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])
alpha-emitting radioimmunotherapy targeting PSMA (Folate Hydrolase 1), anti-PSMA targeting
FOLH1Phase 3Metastatic Castration-resistant Prostate Cancer; Metastatic Prostate CancerJun 2029
Sodium Zirconium Cyclosilicate (SZC)
Selective potassium binder
–Phase 3HyperkalaemiaFeb 2030
Esomeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Erosive Esophagitis; Liver Cirrhosis; Helicobacter Pylori Infections; Radiation Esophagitis …–
AZD0171
Mechanism unclear
–Phase 2Locally Advanced or Metastatic Solid Tumours; Non-small Cell Lung CancerNov 2026
Adavosertib (AZD1775)
Serine/threonine-protein kinase WEE1 inhibitor
WEE1Phase 2Metastatic Triple Negative Breast Cancer; Muscle Invasive Bladder Cancer; Prostate Cancer; Advanced Lymphoma …Nov 2026
AZD2811
Aurora B kinase inhibitor
–Phase 2Small-Cell Lung CancerDec 2026
AZD6234 in combination with AZD9550
Dual GCG and GLP-1 receptor agonist
GCG, GLP1RPhase 2Obesity/Overweight; Healthy Participants; Overweight and Obesity; Hepatic ImpairmentJan 2027
AZD4144–Phase 2Sepsis; HealthyFeb 2027
AZD5148
monoclonal antibody
–Phase 2Clostridioides Difficile InfectionApr 2027
AZD7798–Phase 2Moderate to Severe Crohn's Disease; Crohn's DiseaseMay 2027
ALXN1920
Factor D inhibitor
–Phase 2Primary Membranous NephropathyJul 2027
AZD2389
FAP inhibitor
FAPPhase 2Liver FibrosisJul 2027
AZD6793–Phase 2Chronic Obstructive Pulmonary Disease (COPD)Aug 2027
AZD2373
APOL1-mediated kidney disease inhibitor
APOL1Phase 2APOL1-Mediated Kidney DiseaseOct 2027
ALXN2030–Phase 2Antibody-Mediated Rejection; HealthyOct 2027
Tarperprumig (ALXN1820)
C5a receptor antagonist
–Phase 2Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisOct 2027
AZD1163–Phase 2Rheumatoid ArthritisNov 2027
AZD0292
bispecific IgG1k monoclonal antibody
–Phase 2Bronchiectasis With Pseudomonas Aeruginosa ColonizationDec 2027
Atirmociclib
CDK4/6 inhibitor
CDK4, CDK6Phase 2Advanced Breast CancerDec 2027
AZD8965–Phase 2Idiopathic Pulmonary Fibrosis (IPF)Sep 2028
Rituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 2Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma; Rheumatoid Arthritis (RA); ANCA Associated Vasculitis …Oct 2028
ALXN2220
Factor D complement inhibitor
CFDPhase 2Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Feb 2029
Glycopyrronium
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor
CHRM3, CHRM1, CHRM4, CHRM2, CHRM5Phase 2AsthmaMay 2029
Danvatirsen
STAT-3 mRNA 3'UTR antisense inhibitor
STAT3Phase 2Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced Colorectal Carcinoma; AML/MDS–
Necitumumab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2Non-Small Cell Lung Cancer; Metastatic Lung Non-Small Cell Carcinoma–
Vistusertib
Serine/threonine-protein kinase mTOR inhibitor
MTORPhase 2Non-Small Cell Lung Cancer; Meningioma; Metastatic Breast Cancer; BRCA1 Mutation Carrier–
AZD5305
PARP inhibitor
PARP1, PARP2Phase 1Prostate Cancer; Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer; Ovarian Cancer; Breast Cancer …Nov 2026
AZD9750
AR-PROTAC (proteolysis-targeting chimera)
ARPhase 1Prostate CancerNov 2026
AZD1613–Phase 1Healthy; Autosomal Dominant Polycystic Kidney DiseaseNov 2026
AZD0754
CAR T-cell therapy
–Phase 1Metastatic Prostate CancerNov 2026
Oleclumab
5'-nucleotidase inhibitor
NT5EPhase 1Carcinoma, Non-Small-Cell Lung; Metastatic Microsatellite-stable Colorectal CancerNov 2026
Fexagratinib (AZD4547)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 1Muscle Invasive Bladder Cancer; Metastatic Breast CancerNov 2026
AZD3974–Phase 1Healthy ParticipantsDec 2026
AZD4248–Phase 1Chronic Kidney DiseaseDec 2026
AZD4117
H5N1 avian influenza vaccine
–Phase 1Influenza ADec 2026
AZD5315
H7N9 avian influenza vaccine
–Phase 1Influenza ADec 2026
FPI-2053
Bispecific antibody targeting EGFR and cMET
EGFR, METPhase 1Advanced Solid TumorDec 2026
[111In]-FPI-2107
Imaging agent (indium-111 conjugated to FPI-2053 bispecific antibody targeting EGFR and cM
EGFR, METPhase 1Advanced Solid TumorDec 2026
[225Ac]-FPI-2068
Alpha-emitting radiopharmaceutical (actinium-225) conjugated to bispecific antibody target
EGFR, METPhase 1Advanced Solid TumorDec 2026
cediranib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
KIT, PDGFRB, PDGFRA, FLT1, FLT4Phase 1Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer …Dec 2026
Casdatifan (AB521)–Phase 1Advanced Clear Cell Renal Cell CarcinomaJan 2027
AZD7760
TRPM3 antagonist
–Phase 1Staphylococcus Aureus; Staphylococcus Aureus Bloodstream InfectionMar 2027
AZD0543–Phase 1Human Metapneumovirus InfectionMar 2027
AZD4360
anti-CLDN18.2 antibody-drug conjugate
–Phase 1Gastric CancerMar 2027
AZD1705–Phase 1CardiovascularApr 2027
AZD1043–Phase 1Healthy ParticipantsApr 2027
AZD4954
Lipoprotein(a) (Lp[a]) modulator
–Phase 1Healthy ParticipantsApr 2027
AZD7789 (sabestomig)
anti-PD-1 and anti-TIM-3 bispecific antibody
PDCD1, HAVCR2Phase 1Carcinoma, Non-Small-Cell Lung; Advanced or Metastatic NSCLCMay 2027
AZD5492
CD8/TCR-based T-cell engaging antibody targeting CD20
CD20Phase 1Systemic Lupus Erythematosus; B-cell MalignanciesMay 2027
AZD8421
CDK2 inhibitor
CDK2Phase 1ER+ HER2- Advanced Breast CancerJun 2027
AZD9793
T cell-engaging antibody targeting GPC3 on tumour cells
GPC3Phase 1Hepatocellular CarcinomaJun 2027
Monalizumab (IPH2201)
NKG2-A/NKG2-B type II integral membrane protein inhibitor
KLRC1Phase 1Advanced Solid TumorsJul 2027
ALXN2230–Phase 1Healthy Adult ParticipantsAug 2027
AZD6489
RSV recombinant prefusion F protein virus-like particle (VLP) vaccine
RSVPhase 1RSV Respiratory Syncytial VirusAug 2027
AZD0240
Autologous TCR-engineered T cells targeting KRAS G12D mutation (HLA-A*11:01 or HLA-A*11:02
–Phase 1Non-small Cell Lung CancerAug 2027
NT-112
Autologous TCR-engineered T cells targeting KRAS G12D mutation (HLA-C*08:02 restricted)
–Phase 1Non-small Cell Lung CancerAug 2027
Palacaparib (AZD9574)
PARP inhibitor
PARP1, PARP2Phase 1Breast Cancer; Advanced Solid Malignancies; Metastatic Prostate CancerSep 2027
AZD8359
STEAP2-targeting T cell engager (TCE)
STEAP2Phase 1Metastatic Prostate CancerNov 2027
AZD4063
Phospholamban (PLN) inhibitor targeting R14del mutation
PLNPhase 1Dilated CardiomyopathyNov 2027
MEDI5752
Bispecific antibody targeting TIGIT and CD155 immune checkpoint
–Phase 1Advanced Renal Cell Carcinoma; Selected Advanced Solid TumorsNov 2027
AZD5851
GPC3-directed CAR-T cell therapy
GPRC3Phase 1Hepatocellular CarcinomaDec 2027
AZD4916–Phase 1Healthy ParticipantsDec 2027
AZD0305–Phase 1Multiple MyelomaJan 2028
AZD4512
anti-CD22 antibody-drug conjugate
CD22Phase 1B-cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia (B-ALL)Jul 2028
AZD9592–Phase 1Advanced Solid TumoursAug 2028
AZD2962
IRAK4 inhibitor
IRAK4Phase 1Haematologic NeoplasmsOct 2028
AZD3470
PRMT5 inhibitor
PRMT5Phase 1Advanced Solid Tumors That Are MTAP Deficient; LymphomaDec 2028
AZD0516–Phase 1Metastatic Prostate CancerJan 2029
AZD3632
MLLT3 protein-protein interaction inhibitor; targets menin-KMT2A interaction in KMT2A-rear
MLLT3Phase 1Acute Lymphoblastic LeukaemiaFeb 2029
AZD5863
T cell-engaging bi-specific antibody targeting CLDN18.2 and CD3
CLDN18, CD3EPhase 1Gastric CancerMar 2029
AZD6621
T cell-engaging antibody targeting STEAP2, CD3, and CD8
STEAP2, CD3, CD8Phase 1Prostate CancerMar 2029
AZD2275–Phase 1Metastatic Castration-Resistant Prostate CancerApr 2029
AZD2284
PSMA-targeted alpha-emitting radiopharmaceutical
–Phase 1Metastatic Castration-Resistant Prostate CancerApr 2029
AZD2287–Phase 1Metastatic Castration-Resistant Prostate CancerApr 2029
NT-175
Autologous engineered T cell therapy expressing HLA-A*02:01-restricted TCR targeting TP53
–Phase 1Non-small Cell Lung CancerJul 2029
AZD6750
CD8-targeted IL-2 immunomodulator
IL2Phase 1MelanomaOct 2029
AZD4956
PARP inhibitor
PARP1, PARP2Phase 1Solid TumoursMar 2030
AZD4045
Allogeneic CAR-T cell therapy targeting BCMA (B cell maturation antigen)
TNFRSF17Phase 1Relapsed or Refractory Multiple MyelomaMar 2031
ALXN2350
AAV9-mediated BAG3 gene therapy
BAG3Phase 1BAG3 Mutation Associated Dilated CardiomyopathyJan 2032
AZD1390
ATM inhibitor
ATMPhase 1Recurrent Glioblastoma Multiforme; Non Small Cell Lung Cancer; Solid Tumor–
Atezolizumab (MEDI4736)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 1Ovarian–
Imaradenant (AZD4635)
Adenosine A2a receptor antagonist
ADORA2APhase 1Carcinoma, Non-Small-Cell Lung–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01167712BevacizumabPhase 3Fallopian Tube Endometrioid AdenocarcinomaOncologyDec 2015
NCT02048813RituximabPhase 3AnemiaOncologyOct 2018
NCT01992952CapivasertibPhase 1Estrogen Receptor Positive Breast CancerOncologyMar 2019
NCT03010436BenralizumabPhase 2AsthmaRespiratoryJul 2019
NCT03330847Adavosertib (AZD1775)Phase 2Metastatic Triple Negative Breast CancerOncologyNov 2020
NCT03330847ceralasertibPhase 2Metastatic Triple Negative Breast CancerOncologyNov 2020
NCT02142803BevacizumabPhase 1Adult GlioblastomaOncologyDec 2020
NCT03775486Durvalumab (MEDI4736)Phase 2Non-small Cell Lung Cancer NSCLCOncologyJan 2021
NCT03775486OlaparibPhase 2Non-small Cell Lung Cancer NSCLCOncologyJan 2021
NCT00492050RituximabPhase 2Waldenstrom's MacroglobulinemiaOncologyFeb 2021
NCT03381274OleclumabPhase 1Carcinoma, Non-Small-Cell LungOncologyMay 2021
NCT03381274Imaradenant (AZD4635)Phase 1Carcinoma, Non-Small-Cell LungOncologyMay 2021
NCT02734004OlaparibPhase 1OvarianOncologySep 2021
NCT02734004Atezolizumab (MEDI4736)Phase 1OvarianOncologySep 2021
NCT03653052Durvalumab (MEDI4736)Phase 2Oesophageal CancerOncologyNov 2021
NCT04460248RituximabPhase 2Diffuse Large B Cell LymphomaOncologyFeb 2022
NCT03641755OlaparibPhase 1Breast CancerOncologyApr 2022
NCT04590963MonalizumabPhase 3Squamous Cell Carcinoma of the Head and NeckOncologyMay 2022
NCT03071874VistusertibPhase 2MeningiomaOncologyJun 2022
NCT03704480Durvalumab (MEDI4736)Phase 2Advanced Biliary Tract CarcinomaOncologyJul 2022
NCT03704480TremelimumabPhase 2Advanced Biliary Tract CarcinomaOncologyJul 2022
NCT04590235SelumetinibPhase 1Neurofibromatosis 1OncologyAug 2022
NCT03003962Durvalumab (MEDI4736)Phase 3Non Small Cell Lung Carcinoma NSCLCOncologyOct 2022
NCT02299999Fexagratinib (AZD4547)Phase 2Metastatic Breast CancerOncologyDec 2022
NCT03308396Durvalumab (MEDI4736)Phase 1Advanced Kidney CancerOncologyDec 2022
NCT02299999CapivasertibPhase 2Metastatic Breast CancerOncologyDec 2022
NCT02299999VistusertibPhase 2Metastatic Breast CancerOncologyDec 2022
NCT03932331AcalabrutinibPhase 1Phase I: Relapsed or Refractory B-cell MalignanciesOncologyDec 2022
NCT03795311BevacizumabPhase 1Colorectal CancerOncologyJan 2023
NCT04639219Trastuzumab deruxtecanPhase 2Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,BreastOncologyJan 2023
NCT03161223Durvalumab (MEDI4736)Phase 1Lymphoma, T-CellOncologyFeb 2023
NCT04305496CapivasertibPhase 3Locally Advanced (Inoperable) or Metastatic Breast CancerOncologyMay 2023
NCT03819465Durvalumab (MEDI4736)Phase 1Metastatic Non-Small Cell Lung Cancer (NSCLC)OncologyMay 2023
NCT03819465DanvatirsenPhase 1Metastatic Non-Small Cell Lung Cancer (NSCLC)OncologyMay 2023
NCT03819465OleclumabPhase 1Metastatic Non-Small Cell Lung Cancer (NSCLC)OncologyMay 2023
NCT03819465Volrustomig (MEDI5752)Phase 1Metastatic Non-Small Cell Lung Cancer (NSCLC)OncologyMay 2023
NCT04348045Durvalumab (MEDI4736)Phase 2Metastatic Pancreatic AdenocarcinomaOncologyJun 2023
NCT04348045OlaparibPhase 2Metastatic Pancreatic AdenocarcinomaOncologyJun 2023
NCT04348045SelumetinibPhase 2Metastatic Pancreatic AdenocarcinomaOncologyJun 2023
NCT04308174Durvalumab (MEDI4736)Phase 2Biliary Tract NeoplasmsOncologyJun 2023
NCT03778957Durvalumab (MEDI4736)Phase 3Hepatocellular CarcinomaOncologySep 2023
NCT03778957BevacizumabPhase 3Hepatocellular CarcinomaOncologySep 2023
NCT04940546BevacizumabPhase 1Colorectal Cancer MetastaticOncologyOct 2023
NCT03161353Trastuzumab deruxtecanPhase 2Breast CancerOncologyNov 2023
NCT03828227BevacizumabPhase 3Elderly PatientsOncologyNov 2023
NCT03688451RituximabPhase 2Non Hodgkin LymphomaOncologyDec 2023
NCT03703297Durvalumab (MEDI4736)Phase 3Small Cell Lung CancerOncologyJan 2024
NCT03703297TremelimumabPhase 3Small Cell Lung CancerOncologyJan 2024
NCT03482102Durvalumab (MEDI4736)Phase 2Hepatocellular CarcinomaOncologyFeb 2024
NCT03482102TremelimumabPhase 2Hepatocellular CarcinomaOncologyFeb 2024
NCT04494425Trastuzumab deruxtecanPhase 3Advanced or Metastatic Breast CancerOncologyMar 2024
NCT05061134Durvalumab (MEDI4736)Phase 2MelanomaOncologyApr 2024
NCT05061134ceralasertibPhase 2MelanomaOncologyApr 2024
NCT04333823DapagliflozinPhase 3Diabetes Mellitus, Type 1Metabolic and endocrineMay 2024
NCT04563338BevacizumabPhase 2Hepatocellular CarcinomaOncologyJun 2024
NCT06094140Durvalumab (MEDI4736)Phase 2Pancreatic CancerOncologyJun 2024
NCT03813394BevacizumabPhase 1Locally Recurrent CancerOncologyJul 2024
NCT05601973BevacizumabPhase 2Non Small Cell Lung CancerOncologyAug 2024
NCT05751343BevacizumabPhase 2Hepatocellular CarcinomaOncologyAug 2024
NCT07014280BevacizumabPhase 4KeloidsImmunologySep 2024

The 60 nearest readouts of 1690 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of $5.7bn on 2025-12-31; operating cash flow positive

Complete response letters from FDA

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PARP1 (5) PARP2 (5) EGFR (5) MET (4) PDCD1 (3) ADRB2 (3) CHRM3 (3) CD274 (2) TOP1 (2) GCGR (2) C5 (2) NT5E (2)

Companies with the same targets

Johnson & Johnson (Janssen) Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Pfizer GSK Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Akeso Merck & Co. (MSD) Jiangsu HengRui Medicine Sichuan Baili Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.